Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, December 14, 2021
CellCarta, a global provider of precision medicine laboratory services, announced the acquisition of Biogazelle ("Biogazelle"), a leader in genomic testing solutions. Located in Ghent (Belgium), Biogazelle develops and deploys high-end digital PCR (...
read more
CellCarta, a global provider of precision medicine services, has announced the acquisition of Reveal Biosciences.
read more
CellCarta announced the appointment of Ehab A. El-Gabry, MD, as Chief Medical Officer and Head of Companion Diagnostics. In this role, Dr. El-Gabry will provide medical and scientific leadership across CellCarta's biomarker programs and lead the ...
read more
CellCarta and Olink Proteomics AB announced a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies.
read more
Tuesday, October 10, 2017
Protea Biosciences announced it plans to develop clinical screening assays in various areas of oncology.
read more
Wednesday, January 20, 2016
Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), announced that it entered into a new agreement for the cGMP manufacturing of UCART123 clinical batches, Cellectis’ lead product ...
read more
Cellectis has entered into a lease agreement to build an 82,000 square foot commercial-scale manufacturing facility named IMPACT in Raleigh, North Carolina.
read more
Wednesday, October 02, 2019
Cellectis and Lonza announced the companies have entered into a manufacturing service agreement covering clinical manufacturing of Cellectis’ allogeneic UCART product candidates targeting hematological malignancies.
read more
Wednesday, February 07, 2018
Golden Meditech announced its associate, Cellenkos successfully registered its stand-alone, manufacturing facility as GMP compliant with FDA.
read more
CellGenix is pleased to announce the appointment of Daniel Spatz as Vice President Sales, Marketing & Logistics and member of the management team.
read more
CellGenix GmbH has announced the completion of the second phase of their facility expansion.
read more
Tuesday, February 21, 2017
CellGenix, a global manufacturer of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, started facility expansions as more customers approach late-stage clinical development and commercialization.
read more
Cellipont Bioservices announced a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is pioneering the development of RB-1355, a first of its kind cellular therapy that leverages the versatility and power of a patient...
read more
Thursday, November 20, 2025
Cellipont Bioservices announced a strategic collaboration with Ronawk to accelerate the scalable expansion of high-quality mesenchymal stem cells (MSCs). The partnership addresses key industry challenges in scalability, consistency, capital ...
read more
Tuesday, January 28, 2025
Under this partnership, Cellipont Bioservices will provide technology transfer, analytical method transfer, and cGMP manufacturing for the STM-01 Master Cell Bank. STM-01, a novel nCPC product, is protected under a recently issued composition of ...
read more